首页|期刊导航|Virologica Sinica|Eltrombopag,an FDA-approved drug,inhibits dengue virus type 2 by targeting NS2B-NS3 protease

Eltrombopag,an FDA-approved drug,inhibits dengue virus type 2 by targeting NS2B-NS3 protease

Xuerui Zhu Xiao Gao Yan Wu Jia Lu Xinlan Chen Chenshu Zhao Haoyu Li Zhongfa Zhang Shuwen Liu Gengfu Xiao Xiaoyan Pan

Virologica Sinica2025，Vol.40Issue(3)：P.439-450,12.

Virologica Sinica2025，Vol.40Issue(3)：P.439-450,12.DOI:10.1016/j.virs.2025.05.009

Eltrombopag,an FDA-approved drug,inhibits dengue virus type 2 by targeting NS2B-NS3 protease

Xuerui Zhu ¹Xiao Gao ²Yan Wu ¹Jia Lu ²Xinlan Chen ²Chenshu Zhao ¹Haoyu Li ²Zhongfa Zhang ¹Shuwen Liu ³Gengfu Xiao ²Xiaoyan Pan²

作者信息

1. State Key Laboratory of Virology and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430207,China
2. State Key Laboratory of Virology and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430207,China University of Chinese Academy of Sciences,Beijing 101400,China
3. School of Pharmaceutical Sciences,Southern Medical University,Guangzhou 510515,China
折叠

摘要

关键词

Dengue virus type 2(DENV 2)/Antiviral agent/NS2B-NS3 protease/Eltrombopag/Allosteric inhibitor

分类

医药卫生

引用本文复制引用

Xuerui Zhu,Xiao Gao,Yan Wu,Jia Lu,Xinlan Chen,Chenshu Zhao,Haoyu Li,Zhongfa Zhang,Shuwen Liu,Gengfu Xiao,Xiaoyan Pan..Eltrombopag,an FDA-approved drug,inhibits dengue virus type 2 by targeting NS2B-NS3 protease[J].Virologica Sinica,2025,40(3):P.439-450,12.

基金项目

supported by the National Natural Science Foundation of China(Grant No.82130101) （Grant No.82130101）

the Youth Innovation Promotion Association of CAS(Grant No.2021333). （Grant No.2021333）

Virologica Sinica

ISSN：1674-0769

访问量0

下载量0

段落导航